Novo Nordisk's obesity business doubles in size but still doesn't measure up to estimates

The Danish pharmaceutical giant’s obesity business has had a year-on-year sales growth of 99%, but the firm’s big hope, Wegovy, has not performed as well as expected during the second quarter of 2022.

Photo: Novo Nordisk / PR

Novo Nordisk’s Obesity Care business, which entails the company’s weight loss treatments, has experienced a year-on-year growth spurt. With a 99% sales uptick, the business weighs in at twice as much compared to last year.

Nevertheless, this result did not match what analysts had anticipated before the Danish pharmaceutical giant published its Q2 report on Wednesday. During the months of April, May, and June, sales of the company’s newest obesity drug, Wegovy (semaglutide), came in under what Novo Nordisk had estimated based on analyst projections, booking DKK 1.2bn (USD 164.2m) compared to DKK 1.4bn (USD 191.6m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs